Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...

By Karen Blum The growth of high-cost specialty drugs is causing payors to scramble to manage spending on these products, speakers said...

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...

The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...

This article details the potential regulatory approval pathways.

This article explains potential data and market exclusivity granted during the U.S. regulatory approval process.

This article details the FDA evaluation process and expedited review designations.

This article explains medical drug coding and reimbursement.

This article explains generic drug pricing, associated terms, including MAC rates and lists, biosimilar pricing, and more.

This article answers the question, "how does branded drug pricing work?" defining associated terms such as average wholesale price, wholesal

An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.

Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.

Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.

Competitors in the field of adalimumab and insulin products may soon include authorized biologics.

Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.

IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.

According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.

Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth

Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.